Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
from Top News and Analysis (pro) https://ift.tt/NMRGJX8
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
October 25, 2023
0